Efficacy of the combined use of taurine for hyperbilirubinemia caused by UFT therapy after surgery for colonic cancer

Miyata, K.; Ikawa, O.; Izumi, H.; Shimomura, K.; Matsumura, H.; Kakihara, N.; Katoh, Y.; Ohgaki, M.; Iizuka, R.; Fujii, K.; Shimotsuma, M.; Tkenaka, A.

Gan to Kagaku Ryoho. Cancer and ChemoTherapy 33(5): 671-673

2006


ISSN/ISBN: 0385-0684
PMID: 16685170
Document Number: 595897
For postoperative adjuvant chemotherapy, UFT was administered to 69 cases of stage II and III colonic cancer following surgery with a radical curability of A. Among these patients, 8 developed hyperbilirubinemia. UFT administration was discontinued for those who developed overt jaundice or dermatological symptoms, experienced a relapse of an earlier asthmatic respiratory difficulty, or for those who were found with multiple hepatic metastases. For the 4 who had developed subclinical jaundice with a total bilirubin level of 1.6 to 2.2 mg/dl, UFT was combined with taurine. The combination successfully eliminated hyperbilirubinemia. All 4 are currently alive with no recurrence at this writing. Taurine ameliorates one's capacity to excrete bile, blood flow, and augments the actions of hepatocytes. It is effective in treating the hyperbilirubinemia that develops during UFT therapy.

Document emailed within 1 workday
Secure & encrypted payments